Optimization of Sepsis Therapy Based on Patient-specific Digital Precision Diagnostics
A legfontosabb adatok
- Ki végzi
- University Hospital, Essen
- Hol
- Németország22 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 410 fő vett részt
- Kezdés
- 2022. márc. 16.
- Befejezés
- 2024. ápr. 23.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Standard diagnostics
- Next Generation Sequencing (NGS)
- A regiszteradat frissítve
- 2025. augusztus 24.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- All patients who develop sepsis or septic shock within < 24 h in accordance with the new sepsis definition (Sepsis-3) in the above-mentioned participating centers and consent to participation in the study will be included; General inclusion criteria:
- Written consent by the study participant or a legally appointed representative
- Age >18 years; Sepsis:
- Life-threatening organ dysfunction due to a dysregulated immune response on the basis of a suspected or proven infection
- Detection of organ dysfunction indicated by SOFA score of ≥ 2 points Alternative:; Change of the quick (q) SOFA score of 2 points as an indication of a sepsis; Or septic shock:
- Persistent hypotension despite adequate volume substitution, which necessitates the use of vasopressors, to maintain an arterial medium pressure of > 65 mmHg
- Serum lactate > 2 mmol/l (18 mg/dl)
Ki nem vehet részt
- Palliative therapy approach
- Age < 18 years
- Refusal to participate in the study
- Probable discharge of the patient from the intensive care unit within the first 72 h of initial study inclusion
- Death of the patient is already foreseeable or inevitable at trial inclusion
- Patients who have already been included in the study but require re-admission to the intensive care unit cannot be included a second
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Sepsis is triggered by an infection and represents one of the greatest challenges of modern intensive care medicine. With regard to a targeted antimicrobial treatment strategy, the earliest possible pathogen detection is of crucial importance. Until now, culture-based detection methods represent the diagnostic gold standard, although they are characterized by numerous limitations. Culture-independent molecular diagnostic procedures may represent a promising alternative. In particular, the concept of plasmatic detection of circulating, free DNA employing next-generation sequencing (NGS) has shown to be suitable for the detection of disease-causing pathogens in patients with bloodstream infections.
A teljes eredeti leírásKevesebb
The DigiSep-Trial is a randomized, controlled, interventional, multicenter trial to characterize the effect of the combination of NGS-based digital precision diagnostics, standard-of-care microbiological analyses and optional expert exchanges compared to solely standard-of-care microbiological analyses in the clinical picture of sepsis / septic shock. The study examines in 410 patients (n = 205 per arm) with sepsis / septic shock whether the so-called DOOR-RADAR (Desirability of Outcome Ranking / Response Adjusted for Duration of Antibiotic Risk) score (representing a combined endpoint including the criteria (1) inpatient admission time, (2) consumption of antibiotics, (3) mortality and (4) acute renal failure (ARF)) can be significantly improved, by application of an additional NGS-based diagnostic concept. We also aim to investigate whether the new diagnostic procedure is cost-effective. It is postulated that the inpatient admission time, mortality rate, incidence of ARF, the duration of antimicrobial therapy as well as the costs of complications and outpatient aftercare can be reduced. Moreover, a significant improvement in the quality of life (QoL) of the affected patients can be expected.
Extensive preparatory work suggests that NGS-based diagnostics have higher specificity and sensitivity compared to standard-of-care microbiological analyses for detecting bloodstream infections. This preliminary work for the DigiSep-Trial with the help of an interventional study design provides the optimal basis to establish this new concept as part of the national standard based on the best possible evidence.
A vizsgálat 2 csoportja
- 1Már használt kezelés, összehasonlításként
Standard diagnostics
Kezelés: Standard diagnostics
- 2A vizsgált kezelés
Standard diagnostics + NGS
Kezelés: Next Generation Sequencing (NGS)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Publikációk
- Effects of a clinical metagenomics intervention on clinical outcomes, healthcare costs, and health-related quality of life in patients with sepsis or septic shock: results of the randomized-controlled DigiSep trial.Intensive care medicine, 2026
- Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)-study protocol for a randomized, controlled, interventional, open-label, multicenter trial.Trials, 2021
- A regiszteradat frissítve
- 2025. augusztus 24.